|
WO2010082912A1
|
|
Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
|
|
EP2170311A1
|
|
Compounds and methods for treating or preventing autoimmune diseases
|
|
MX2009011970A
|
|
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof.
|
|
WO2008133975A1
|
|
Multi-ring compounds and uses thereof
|
|
WO2008070160A2
|
|
Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
|
|
EP2044247A2
|
|
Chemo-selective identification of therapeutics
|
|
EP1991233A2
|
|
Hydroxypiperidine derivatives and uses thereof
|
|
WO2006002378A2
|
|
Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
|
|
US2008305493A1
|
|
Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
|
|
WO2005082030A2
|
|
Chemo-centric selection of disease-related genetic profiles
|
|
WO2005067629A2
|
|
Cancer-linked genes as targets for chemotherapy
|
|
WO2005062788A2
|
|
Prostate specific proteins expressed in cancer and methods of use thereof
|
|
WO2005035724A2
|
|
Cancer-linked genes as targets for chemotherapy
|
|
WO2005013903A2
|
|
Derivatives of substituted quinone and uses thereof
|
|
WO2005016000A1
|
|
Derivatives of cyclic quinone and uses thereof
|
|
WO2005016264A2
|
|
Diamine derivatives of quinone and uses thereof
|
|
US2007270504A1
|
|
Identification of Therapeutic Agents Using Genetic Fingerprinting
|
|
WO2005002417A2
|
|
Cancer -linked gene aas target for chemotherapy
|
|
WO2005017104A2
|
|
Cancer-linked gene as target for chemotherapy
|
|
US2007059697A1
|
|
Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
|
